Selected article for: "death respiratory failure and SARS CoV Respiratory Syndrome coronavirus"
Author: Alberca, Ricardo Wesley; Teixeira, Franciane Mouradian Emidio; Beserra, Danielle Rosa; de Oliveira, Emily Araujo; Andrade, Milena Mary de Souza; Pietrobon, Anna Julia; Sato, Maria Notomi
Title: Perspective: The Potential Effects of Naringenin in COVID-19
  • Cord-id: okvt1fg3
  • Document date: 2020_9_25
    • ID: okvt1fg3
    Snippet: Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), was declared a pandemic by the World Health Organization in March 2020. Severe COVID-19 cases develop severe acute respiratory syndrome, which can result in multiple organ failure, sepsis, and death. The higher risk group includes the elderly and subjects with pre-existing chronic illnesses such as obesity, hypertension, and diabetes. To date, no specific treatment or vaccine is available
    Document: Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), was declared a pandemic by the World Health Organization in March 2020. Severe COVID-19 cases develop severe acute respiratory syndrome, which can result in multiple organ failure, sepsis, and death. The higher risk group includes the elderly and subjects with pre-existing chronic illnesses such as obesity, hypertension, and diabetes. To date, no specific treatment or vaccine is available for COVID-19. Among many compounds, naringenin (NAR) a flavonoid present in citrus fruits has been investigated for antiviral and anti-inflammatory properties like reducing viral replication and cytokine production. In this perspective, we summarize NAR potential anti-inflammatory role in COVID-19 associated risk factors and SARS-CoV-2 infection.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and adipose tissue: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and load control: 1
    • acute ards respiratory distress syndrome and low respiratory tract: 1, 2
    • acute ards respiratory distress syndrome and lps induce: 1, 2, 3, 4, 5, 6
    • acute ards respiratory distress syndrome and lps induce model: 1
    • acute lung injury and ade antibody dependent enhancement: 1
    • acute lung injury and adipose tissue: 1, 2
    • acute lung injury and low respiratory tract: 1
    • acute lung injury and lps induce: 1, 2, 3, 4, 5, 6
    • acute respiratory and ade antibody dependent enhancement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and adipose tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and adjuvant effect: 1, 2, 3, 4, 5, 6
    • acute respiratory and load control: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory and low respiratory tract: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute respiratory and lps induce: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory and lps induce model: 1
    • acute respiratory syndrome and low respiratory tract: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and lps induce: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory syndrome and lps induce model: 1